National Research Council of Canada. Human Health Therapeutics
AACR 107th Annual Meeting 2016, April 16-20, 2016, New Orleans, LA
One of the most promising and fastest growing classes of cancer therapeutics builds on the molecular targeting abilities of antibodies by combining them with drugs to generate highly specific antibody-drug conjugates (ADCs). However, the development of ADCs requires time-consuming selection of the antibody for every target and cancer type. Screening technologies based on the use of conjugated secondary antibodies provide a fast and efficient surrogate assay from which to identify which antibodies are best internalized and suitable for immunoconjugate development into ADCs.
Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA.